Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
CAR-T cells Infusion chimeric antigen receptor T cells
The First People's Hospital of Lianyungang
Relapsed/Refractory Plasma Cell Leukemia
1 trial -
CARTmeso CART19
The First People's Hospital of Lianyungang
Pancreatic Cancer
1 trial -
CBG131 CAR-T Cell Infusion
The First People's Hospital of Lianyungang
Advanced Gastric and Pancreatic Cancer
1 trial -
CD19 and BCMA-targeted allogeneic CAR-T cells
The First People's Hospital of Lianyungang
Refractory Immune-mediated Platelet Transfusion Refractoriness
1 trial -
CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing
The First People's Hospital of Lianyungang
Refractory Idiopathic Membranous Nephropathy
1 trial -
CS-101
The First People's Hospital of Lianyungang
Beta-Thalassemia
1 trial -
CT-996
The First People's Hospital of Lianyungang
Type 2 Diabetes
1 trial -
CTA101
The First People's Hospital of Lianyungang
Diffuse Large B-cell Lymphoma
1 trial -
CVA
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Chimeric antigen receptor T cell
The First People's Hospital of Lianyungang
Pancreatic Cancer
1 trial -
Chinese Herbal Compound Ointment
The First People's Hospital of Lianyungang
Atrophic Vaginitis
1 trial -
ClinOleic (Baxter Healthcare, Deerfield, IL, USA)
The First People's Hospital of Lianyungang
Nutritional Supplement Toxicity
1 trial -
Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma (DLBCL)
1 trial -
Dexlansoprazole Injection
The First People's Hospital of Lianyungang
Effect of Drugs
1 trial -
Dexmedetomidine
The First People's Hospital of Lianyungang
Heart Injuries
1 trial -
Dexmedetomidine
The First People's Hospital of Lianyungang
Cesarean Section, Affecting Fetus or Newborn
1 trial -
Digoxin
The First People's Hospital of Lianyungang
Healthy
1 trial -
Eprolidone
The First People's Hospital of Lianyungang
Chronic Heart Failure Patients
1 trial -
Esketamine injection group (0.25 mg/kg)
The First People's Hospital of Lianyungang
Esketamine
1 trial -
Exenatide Circular RNA-Lipid Nanoparticle InjectionοΌ CR059οΌοΌ
The First People's Hospital of Lianyungang
T2DM
1 trial -
FT-003
The First People's Hospital of Lianyungang
Neovascular Age-related Macular Degeneration
1 trial -
FT-003
The First People's Hospital of Lianyungang
Diabetic Macular Edema
1 trial -
Ferric Carboxymaltose Injection
The First People's Hospital of Lianyungang
Healthy Adult
1 trial -
Fimasartan
Yung NA
Essential Hypertension
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources